Kenai Therapeutics develops allogeneic dopamine neuron replacement therapies using induced pluripotent stem cell (iPSC) technology to address neurodegenerative movement disorders, particularly Parkinson's disease. Their lead candidate, RNDP-001, aims to reverse disease progression by replacing lost neurons, demonstrating superior survival and behavioral rescue in preclinical models.
Funding
$86.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Parkinson's disease and other neurodegenerative movement disorders result in the loss of dopamine neurons, leading to debilitating motor and non-motor symptoms. Current treatments provide symptomatic relief but do not address the underlying neurodegeneration or restore lost neuronal function. There is a need for disease-modifying therapies that can replace damaged neurons and reverse disease progression.
Solution
Kenai Therapeutics is developing allogeneic dopamine neuron replacement therapies using induced pluripotent stem cell (iPSC) technology to treat neurodegenerative conditions. Their approach involves replacing neurons lost due to neurodegeneration with healthy, functional dopamine neurons derived from iPSCs. The company's lead candidate, RNDP-001, is an iPSC-derived dopamine progenitor designed to reverse disease progression in both idiopathic and inherited forms of Parkinson's disease. Preclinical studies of RNDP-001 have demonstrated superior survival, innervation, and behavioral rescue. Kenai's platform also includes next-generation, gene-modified programs with the potential to further enhance therapeutic efficacy and address a broader range of central nervous system conditions.
Target Audience
The primary target audience includes patients with moderate to severe Parkinson's disease, inherited forms of Parkinson's disease, and potentially other central nervous system disorders characterized by neuronal loss.
Features
- Allogeneic dopamine neuron progenitors derived from iPSCs for off-the-shelf availability
- RNDP-001: Lead candidate targeting moderate to severe Parkinson's disease and inherited Parkinson's disease
- RNDP-002: Gene-modified iPSC-derived dopamine neuron progenitor for mild to severe rapid progressing Parkinson’s Disease
- RNDP-003: Gene-modified iPSC-derived dopamine neuron progenitor for young onset Parkinson’s Disease
- Proprietary platform for generating and differentiating iPSCs into functional dopamine neurons
- Preclinical data demonstrating neuronal survival, innervation, and behavioral rescue
- Gene-modified programs to enhance therapeutic potential